Dine Therapeutics

Overview

Late-stage rare disease biotech led by CEO John Cox; underwent a two-year organizational transformation from early-stage to launch-ready and is considering continuous manufacturing as a strategic cannonball investment. Dine Therapeutics underwent a fundamental organizational transformation over approximately two years under John Cox, evolving from early-stage to launch-ready, with the core culture preserved while the structure changed significantly. Dine operates with only two committees — one bridging research and development, another bridging clinical development and commercial — to enable fast and accountable decision-making while minimizing bureaucracy. (Segment 2 (05:00-10:00))